Liquidity (Details) (USD $)	0 Months Ended	3 Months Ended			9 Months Ended		12 Months Ended					12 Months Ended
	Jun. 28, 2013	Mar. 31, 2014	Mar. 31, 2013	Sep. 30, 2012	Mar. 31, 2014	Mar. 31, 2013	Jun. 30, 2013		Jun. 30, 2012	Sep. 06, 2012	Sep. 06, 2011	Mar. 31, 2015 Scenario, Forecast [Member]
Cash and cash equivalents		$ 816,000	$ 5,100,000		$ 816,000	$ 5,100,000	$ 2,290,000	[1]	$ 1,899,000
Net losses		(1,664,000)	(1,005,000)		(4,083,000)	(3,045,000)	(4,292,000)		(4,695,000)
Accumulated aggregate net losses from inception of business		(123,101,000)			(123,101,000)		(119,018,000)	[1]
Licensing fee paid											500,000
Total initial licensing fee											1,000,000
Amount owed for current outstanding Prostiva liabilities prior to Restructuring Agreement										500,000
Amount of liabilities restructured	7,500,000
Cash paid related to Restructuring Agreement.	2,000,000
Promissory note payable	5,300,000	5,300,000			5,300,000
Promissory note, interest rate		6.00%			6.00%
Gain on debt extinguishment							206,000
Accrued royalties		650,000			650,000
License maintence fee		65,000			65,000
Shares of common stock sold				5,980,000
Shares price of common stock sold				$ 0.75
Net proceeds from secondary offering						3,814,000
Line of credit, initiation date					Jan. 11, 2012
Line of credit, maximum borrowing capacity		2,000,000			2,000,000
Percentage of eligible accounts receivable used for defined borrowing of line of credit					80.00%
Estimated expense reduction due to restructuring												4,000,000
Accrued royalties and license maintenance fee		$ 715,000			$ 715,000

[1] The Balance Sheet at June 30, 2013 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.